FDA Approved: COSENTYX — Original Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved the original application for Cosentyx (secukinumab), a monoclonal antibody targeting IL-17A, for the treatment of plaque psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

ORIG AP for COSENTYX (SECUKINUMAB)